Pharmacia slams price of Celebrex in Australia
Pharmacia has claimed that it is being paid less for the COX-2 inhibitorCelebrex (celecoxib) in Australia than anywhere in the world. The firm, which co-markets the drug with Pfizer, was defending itself against charges of making excessive profits (Marketletter June 11).
In a cost-saving move, after consulting Federal Health Minister Michael Wooldridge, Pharmacia introduced a pack of 30 tablets to replace the previous 60 pack.
Further highlighting the uncertainty over the future of the Pharmaceutical Benefits Scheme, the Royal Australian College of General Practitioners has offered to draw up guidelines to control high prescribing levels of new drugs such as Celebrex and GlaxoSmithKline's smoking cessation drug Zyban (bupropion).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze